Lovo works for
any manufacturing process.

Select an application
  • Immunomagnetic Selection Prep
  • Fresh Leukapheresis Wash
  • Culture Harvest & Media Exchange
  • Thawed Wash & DMSO Removal
Applications

Immunomagnetic Selection Prep

Lovo can automate preparation for magnetic selections, simplifying and expediting day 0 processing. With Lovo 3.0 software, you have the option to incorporate mid-procedure, timed incubations in your protocol design.

  • Overview
  • Data
Measure Result
Source Products Collections n=5
Volume 163.3 ± 28.5 mL
Total Nucleated Cells (TNC) 10.9 ± 3.4 x 109
Platelet Count 4.46 ± 0.92 x 10 11
Processing Time Automated Processing Time (With incubation) 58 minutes
Max Processing Time 61 minutes

Source: Data on file 223-REP-048957

Measure Result
2 wash cycles to remove platelets and prepare for incubation Platelet Depletion 98.4 ± 1.0%
Targeted Pre-Incubation Volume 100 mL
Actual Pre-Incubation Volume 100.6 ± 1.2 mL
Full Procedure TNC recovery 97.2 ± 3.7%
TNC Viability 96.3 ± 1.4%

Source: Data on file 223-REP-048957

Applications

Fresh Leukapheresis Wash

Quickly and easily remove platelets from leukapheresis products while recovering TNCs and maintaining cell viability.

  • Overview
  • Data
Measure Result
Collections
(5L)
Fenwal Amicus n=6
Spectra Optia n=8
Source Volume 90.8 ± 10.2 ml
TNC 4.7 ± 1.8 x 109
Final
Product
TNC Recovery 98.6%
TNC Viability 97.5%
Target Final Volume 95 mL
Actual Final Volume 95.3 ± 0.6 mL
Processing Time Average 11:01 min
Maximum 11:29 min

Source: Data on file 223-REP-048957

Pre/Post Lovo Wash Platelet Count & Depletion

Source: Data on file 223-REP-048957

Applications

Culture Harvest & Media Exchange

Quickly and easily wash and concentrate up to 22L of cultured cells in one automated and functionally closed system.

Study objective

  • Compare T-Cell harvest methods

Goals

  • Reduce volume from 1.7L to 150mL
  • >99% (2 log) reduction of ancillary materials
  • High cell recovery
  • Maintain cellular CQAs
Cell Type Lovo
Fresenius Kabi
CS5+
Haemonetics
Manual
Recovery (%) 93 ± 4 87 ± 3 91 ± 4
Processing Time (min) 30 ± 1 25 ± 4 61 ± 11
Washout Efficiency (%) 99.5 99.9 99.8
Final Volume (mL) 150 ± 1 153 ± 3 151 ± 6
Cellular CQAs1 comparable
Automated ± x
Functionally Closed ± x

1 Critical Quality Attributes (CQAs) Measured: viability assessment, phenotype, cell functionality, ancillary materials.

Source: Presented by Ian Gaudet, PhD. Senior Engineer, PCT. IBC Commercialization of Cell, Gene, and Immunotherapies, San Diego, CA. 2014.

Applications

Thawed Wash & DMSO Removal

Wash cryopreserved products and resuspend cells in your preferred buffer or culture media.

  • Overview
  • Data
Measure Lovo 2.0
(three-cycle)
Number of Runs 6
PCV% 8.4% (6.9 - 11.4)
Viable CD34+ Cell Recovery 84% (61 - 93)
CD34+ Cell Viability 92% (81 - 94)
DMSO Elimination 97% (97 - 98)
Total Processing Time 62 min

† Data is expressed as median and (IQR)

Source: Mfarrej B., Bouchet G., Couquiaud J., Regimbaud L., Binninger S., Mercier M., … Calmels B. (2017) Pre-clinical assessment of the Lovo device for dimethyl sulfoxide removal and cell concentration in thawed hematopoietic progenitor cell grafts. Cytotherapy, 2017.

3-Cycle Wash1

Post Thaw Recovery

Source: Mfarrej B., Bouchet G., Couquiaud J., Regimbaud L., Binninger S., Mercier M., … Calmels B. (2017) Pre-clinical assessment of the Lovo device for dimethyl sulfoxide removal and cell concentration in thawed hematopoietic progenitor cell grafts. Cytotherapy, 2017.

Have more questions?

Contact A Specialist

Stay Informed.

Sign up below to receive the latest Lovo news and updates.

See Us In Action.

Come see what Lovo’s all about. We’ll walk you through the features and arrange a demo.

American Society for Apheresis (ASFA)
April 25-28
Chicago, IL

The LOVO Cell Processing system is for laboratory use only. Unless the user has obtained advance clearance or approval from the appropriate regulatory agency, cells processed on this system are not intended for diagnostic purposes, direct transfusion, or for use in the production of therapeutic products or vaccines for clinical use. For applications requiring regulatory clearance or approval, users may obtain the required LOVO information from Fresenius Kabi to support their submission.